Our work provides a valuable model for examining the consequences of mTORC1 hyperactivation, understanding human liver pathologies associated with HCV, NASH and DEPDC5 variation, and developing therapeutic strategies for treating such pathologies with mTORC1 inhibitors or antioxidant compounds. The gene discussed is DEPDC5; the disease is metabolic dysfunction-associated steatohepatitis.